CTMX (CytomX Therapeutics) Cyclically Adjusted Book per Share: $1.29 (As of Mar. 2026)


CTMX CytomX Therapeutics Inc CTMX
36 GF Score
Price $3.38
GF Value $0.28
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CytomX Therapeutics Cyclically Adjusted Book per Share?

CytomX Therapeutics CTMX +3.66% 36 Cyclically Adjusted Book per Share is $1.29 as of Mar. 2026. GuruFocus rates CTMX with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

CytomX Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $1.470. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $1.29 for the trailing ten years ended in Mar. 2026.

During the past 12 months, CytomX Therapeutics's average Cyclically Adjusted Book Growth Rate was -4.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-06-27), CytomX Therapeutics's current stock price is $3.38. CytomX Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $1.29. CytomX Therapeutics's Cyclically Adjusted PB Ratio of today is 2.62.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CytomX Therapeutics was 4.25. The lowest was 0.34. And the median was 1.55.


CytomX Therapeutics  (NAS:CTMX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

CytomX Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.38/1.29
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of CytomX Therapeutics was 4.25. The lowest was 0.34. And the median was 1.55.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


CytomX Therapeutics Cyclically Adjusted Book per Share Related Terms


CytomX Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for CytomX Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytomX Therapeutics Cyclically Adjusted Book per Share Chart

CytomX Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 1.36 1.34

CytomX Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.35 1.32 1.45 1.34 1.29

CTMX vs SMNR, AURA, OMER: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, CytomX Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytomX Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's Cyclically Adjusted PB Ratio falls into.


CTMX
36GF Score
CytomX Therapeutics Inc CTMX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytomX Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytomX Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.47/330.2130*330.2130
=1.470

Current CPI (Mar. 2026) = 330.2130.

CytomX Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 2.796 241.018 3.831
201609 2.457 241.428 3.361
201612 2.151 241.432 2.942
201703 2.010 243.801 2.722
201706 1.418 244.955 1.912
201709 1.226 246.819 1.640
201712 1.816 246.524 2.432
201803 1.276 249.554 1.688
201806 1.054 251.989 1.381
201809 3.504 252.439 4.584
201812 2.903 251.233 3.816
201903 2.714 254.202 3.526
201906 2.236 256.143 2.883
201909 1.808 256.759 2.325
201912 1.123 256.974 1.443
202003 1.519 258.115 1.943
202006 1.274 257.797 1.632
202009 1.040 260.280 1.319
202012 -0.161 260.474 -0.204
202103 2.246 264.877 2.800
202106 2.010 271.696 2.443
202109 1.712 274.310 2.061
202112 -0.007 278.802 -0.008
202203 1.043 287.504 1.198
202206 0.741 296.311 0.826
202209 0.432 296.808 0.481
202212 -1.295 296.797 -1.441
202303 -1.306 301.836 -1.429
202306 -1.273 305.109 -1.378
202309 -0.766 307.789 -0.822
202312 -0.705 306.746 -0.759
202403 -0.465 312.332 -0.492
202406 -0.400 314.175 -0.420
202409 -0.300 315.301 -0.314
202412 -0.006 315.605 -0.006
202503 0.311 319.799 0.321
202506 0.727 322.561 0.744
202509 0.651 324.800 0.662
202512 0.582 324.054 0.593
202603 1.470 330.213 1.470

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $1.29 mean?
CytomX Therapeutics (CTMX) has a Cyclically Adjusted Book per Share of $1.29 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors.
Is CytomX Therapeutics' Cyclically Adjusted Book per Share too high?
CytomX Therapeutics' current Cyclically Adjusted Book per Share is $1.29. Overall, CytomX Therapeutics has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Cyclically Adjusted Book per Share compare to SMNR and AURA?
CytomX Therapeutics' Cyclically Adjusted Book per Share of $1.29 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on CytomX Therapeutics and its competitors. CytomX Therapeutics's current Cyclically Adjusted Book per Share is $1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $3.38 — trading 1107.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is $1.29. CytomX Therapeutics' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Cyclically Adjusted Book per Share is $1.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytomX Therapeutics (CTMX) Overvalued in 2026?

Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued. The current stock price of $3.38 is trading 1107.1% above its estimated GF Value™ of $0.28. GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.

Key valuation signals for CTMX:

  • Cyclically Adjusted Book per Share: $1.29
  • GF Value™: $0.28 vs. price of $3.38 (1107.1% above fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CytomX Therapeutics Business Description

Other Exchanges 6C1:Germany
Address 151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
36GF Score

Get the complete analysis for CTMX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.38
Price
$0.28
GF Value